Van ECK Associates Corp Has $428.48 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Van ECK Associates Corp boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 2.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,069,238 shares of the company’s stock after purchasing an additional 518,988 shares during the quarter. Van ECK Associates Corp’s holdings in Kenvue were worth $428,478,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Leo Wealth LLC grew its stake in shares of Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after purchasing an additional 481 shares during the period. Alerus Financial NA boosted its holdings in Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after buying an additional 491 shares during the last quarter. Kiley Juergens Wealth Management LLC grew its position in shares of Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after buying an additional 500 shares during the period. Principle Wealth Partners LLC increased its stake in shares of Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock valued at $303,000 after acquiring an additional 500 shares during the last quarter. Finally, Wolff Wiese Magana LLC raised its position in shares of Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock valued at $1,781,000 after acquiring an additional 501 shares during the period. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

KVUE has been the subject of a number of analyst reports. Bank of America boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Canaccord Genuity Group dropped their price objective on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Finally, Barclays lowered their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $23.00.

Kenvue Stock Up 0.2 %

Shares of Kenvue stock opened at $20.96 on Thursday. The firm has a market cap of $40.19 billion, a PE ratio of 39.55, a P/E/G ratio of 2.16 and a beta of 1.45. The business’s 50 day simple moving average is $21.41 and its 200 day simple moving average is $22.03. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts predict that Kenvue Inc. will post 1.05 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.91%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.